11ò-Hydroxytestosterone is an endogenous steroid, a metabolite of testosterone. Although it may not have significant androgenic activity, it may still be an important precursor to androgenic molecules.
11ò-Hydroxytestosterone is an androstanoid with the molecular formula C<sub>19</sub>H<sub>28</sub>O<sub>3</sub> and a molecular weight of 304.42 Da. Its IUPAC name is (8S,9S,10R,11S,13S,14S,17S)-11,17-dihydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one, reflecting its steroid structure with hydroxyl groups at the 11ò and 17ò positions and a 3-keto group on the A-ring.
The compound is a 3-oxo-ÃÂ4 steroid, structurally related to testosterone, with an additional hydroxyl group at the 11ò-position, which reduces its androgenic potency but enables further metabolism into active androgens.
It is moderately soluble in water due to its hydroxyl groups but more soluble in organic solvents like ethanol.
11ò-Hydroxytestosterone is biosynthesized in the adrenal glands, primarily in the zona reticularis, through the action of cytochrome P450 11ò-hydroxylase (CYP11B1), which catalyzes the hydroxylation of testosterone at the 11ò-position. This enzyme, encoded by the CYP11B1 gene, is a mitochondrial P450 monooxygenase that also converts 11-deoxycortisol to cortisol and 11-deoxycorticosterone to corticosterone, with weaker activity on testosterone. The reaction requires electron transfer from NADPH via adrenodoxin reductase and adrenodoxin, similar to other P450 systems.
In adrenal tissue, testosterone, derived from androstenedione via 17ò-hydroxysteroid dehydrogenase (17òHSD), serves as the precursor. Studies from the 1960s confirmed its production in human adrenal homogenates, with 11ò-Hydroxytestosterone as the predominant metabolite of testosterone, alongside minor amounts of 11ò-hydroxyandrostenedione (11OHA4) and 11-ketoandrostenedione (11KA4). Its biosynthesis is regulated by adrenocorticotropic hormone (ACTH), which upregulates CYP11B1 expression.
In peripheral tissues, 11ò-Hydroxytestosterone is metabolized by 11ò-hydroxysteroid dehydrogenase type 2 (11òHSD2) to 11-ketotestosterone (11-KT), a more potent androgen, or by 5ñ-reductase to 11ò-hydroxydihydrotestosterone (11OHDHT), both of which are androgen receptor (AR) agonists.
11ò-Hydroxytestosterone has weak androgenic activity compared to testosterone or dihydrotestosterone (DHT) due to the 11ò-hydroxyl group, which reduces its affinity for the androgen receptor. However, it is a critical precursor in the C11-oxy C19 steroid pathway, which produces potent androgens like 11-KT and 11-KDHT, particularly in peripheral tissues such as the prostate. This pathway challenges the traditional view that testosterone and DHT are the sole potent androgens in humans.
Recent research has focused on the C11-oxy C19 steroid pathway, with 11ò-Hydroxytestosterone identified as a key intermediate. A 2013 study in LNCaP prostate cancer cells demonstrated its conversion to 11-KT and 11-KDHT, highlighting its role in CRPC. A 2016 study confirmed its elevated levels in 21-hydroxylase deficiency, another form of CAH, where it contributes to adrenal androgen excess.
Given its anabolic properties, 11ò-Hydroxytestosterone is monitored in anti-doping testing. It can be detected in urine samples as part of testing for banned substances. Its detection helps identify the misuse of testosterone or other anabolic steroids, as athletes may attempt to mask their use of these substances by metabolizing testosterone into 11ò-hydroxytestosterone. Specialized tests are used to measure the ratio of 11ò-Hydroxytestosterone to testosterone, as a way to flag illicit use of exogenous substances.